Identification and pre‐clinical investigation of 3‐O‐cyclohexanecarbonyl‐11‐keto‐β‐boswellic acid as a drug for external use to treat psoriasis
British Journal of Pharmacology · 2024-04 · 181 (8) · 1290-1307
DOI: 10.1111/bph.16253 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Pharmacology, online erschienen am 11.01.2024. Verfasst von Fangzhou Lou und 6 weiteren Autor:innen. Beteiligte Einrichtung: Precision Research Center for Refractory Diseases, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Psoriasis, Dermatitis, Triterpenes. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Clinical Research Plan of Shanghai Shenkang Hospital Development Center, Integrated innovation fund of Shanghai Jiao Tong University, National Key Research and Development Program of China.
Abstract (Originalsprache)
Background and Purpose Psoriasis vulgaris is a refractory skin inflammatory disorder with 80% of the cases belonging to the mild‐to‐moderate type, which can be controlled by topical treatment. Nevertheless, the drugs for external use have not been upgraded for decades. We modified acetyl‐11‐keto‐beta‐boswellic acid (ABKA), a natural compound shown to treat psoriasis animal models, to improve efficacy and solubility for topical use. Experimental Approach Eleven compounds were synthesized using AKBA as a lead compound, and their effects on Th17 cell differentiation were screened. 3‐O‐cyclohexanecarbonyl‐11‐keto‐β‐boswellic acid (CKBA) potently inhibited Th17 cell differentiation. Its efficacy in a mouse model of psoriasis was assessed along with its pharmacology and safety profile when topically or systemically delivered to several animal species. Key Results CKBA inhibited mouse and human Th17 cell differentiation with an IC 50 of 3.28 and 3.61 μM, respectively, and directly targeted acetyl‐CoA carboxylase 1 (ACC1). Safety evaluation and toxicity tests suggested that systemically delivered high‐dose CKBA for 14 days had no dose‐associated adverse effects on the CNS, haematopoietic, cardiovascular, respiratory and digestive systems of cynomolgus monkeys. CKBA ointment permeated the skin and did not irritate or sensitize intact skin. CKBA ointment mediated dose‐dependent suppression of imiquimod‐induced psoriasis‐like skin inflammation with slow absorption and limited bioavailability (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Precision Research Center for Refractory Diseases, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- BCY Pharm Co., Ltd., Suzhou, China.
- The Department of Cardiovascular Medicine, State Key Laboratory of Medical Genomics, Shanghai Key Laboratory of Hypertension, Ruijin Hospital, Shanghai Institute of Hypertension, Shanghai Jiao Tong University School of…
ORCID-Profile: Honglin Wang
Förderung
- Clinical Research Plan of Shanghai Shenkang Hospital Development Center
- Integrated innovation fund of Shanghai Jiao Tong University
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- Shanghai Scientific and Technological Innovation Action Plan
- SJTU Trans-med Awards Research
Zitieren
APA
Lou, F., Xu, Z., Bai, J., Zhao, X., Cui, L., Li, Q., & Wang, H. (2024). Identification and pre‐clinical investigation of 3‐O‐cyclohexanecarbonyl‐11‐keto‐β‐boswellic acid as a drug for external use to treat psoriasis. British Journal of Pharmacology, 181(8), 1290-1307. https://doi.org/10.1111/bph.16253
Vancouver
Lou F, Xu Z, Bai J, Zhao X, Cui L, Li Q, et al. Identification and pre‐clinical investigation of 3‐O‐cyclohexanecarbonyl‐11‐keto‐β‐boswellic acid as a drug for external use to treat psoriasis. British Journal of Pharmacology. 2024;181(8):1290-1307. doi:10.1111/bph.16253
BibTeX
@article{Lou2024,
author = {Lou, Fangzhou and Xu, Zhenyao and Bai, Jing and Zhao, Xing'e and Cui, Linlin and Li, Qun and Wang, Honglin},
title = {Identification and pre‐clinical investigation of 3‐O‐cyclohexanecarbonyl‐11‐keto‐β‐boswellic acid as a drug for external use to treat psoriasis},
journal = {British Journal of Pharmacology},
year = {2024},
volume = {181},
number = {8},
pages = {1290--1307},
doi = {10.1111/bph.16253}
}
EUVIMED